Fumitaka Suzuki Selected Research

Hepatitis

1/2014	Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis.
8/2012	Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
2/2010	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.
1/2010	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.
3/2009	Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
1/2009	The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.
11/2008	Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis.
1/2008	Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
1/2008	Changes in viral loads of lamivudine-resistant mutants during entecavir therapy.
10/2007	Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fumitaka Suzuki Research Topics

Disease

84	Hepatocellular Carcinoma (Hepatoma) 04/2022 - 01/2002
80	Infections 10/2022 - 01/2002
61	Chronic Hepatitis B 10/2022 - 01/2002
61	Chronic Hepatitis C 10/2022 - 01/2002
52	Fibrosis (Cirrhosis) 10/2022 - 01/2002
31	Liver Cirrhosis (Hepatic Cirrhosis) 02/2020 - 01/2002
29	Hepatitis 01/2014 - 01/2002
24	Neoplasms (Cancer) 04/2022 - 01/2003
21	Liver Diseases (Liver Disease) 10/2022 - 01/2002
20	Hepatitis B 01/2022 - 01/2002
18	Chronic Hepatitis (Chronic Active Hepatitis) 03/2014 - 01/2003
13	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2009
12	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2009
11	Anemia 01/2017 - 07/2004
11	Carcinogenesis 01/2014 - 01/2003
10	Hepatitis C 11/2015 - 09/2005
8	Liver Neoplasms (Liver Cancer) 10/2022 - 12/2010
8	Diabetes Mellitus 01/2022 - 11/2008
6	Virus Diseases (Viral Diseases) 04/2021 - 01/2004
6	Disease Progression 01/2021 - 01/2004
5	Body Weight (Weight, Body) 01/2018 - 10/2007
5	Viremia 01/2017 - 01/2007
4	Insulin Resistance 01/2022 - 06/2009
4	Hepatic Encephalopathy 12/2019 - 10/2004
4	Hypertension (High Blood Pressure) 03/2014 - 09/2009
4	Persistent Infection 10/2013 - 05/2005
3	Fatty Liver 04/2022 - 09/2009
3	Lymphoma (Lymphomas) 12/2019 - 04/2003
3	Pruritus (Itching) 09/2018 - 10/2016
3	Thrombocytopenia (Thrombopenia) 10/2017 - 05/2009
3	Fever (Fevers) 10/2016 - 03/2012
3	Headache (Headaches) 10/2016 - 04/2013
3	Liver Failure 09/2012 - 01/2004
2	Inflammation (Inflammations) 04/2022 - 01/2012

Drug/Important Bio-Agent (IBA)

80	InterferonsIBA 12/2020 - 01/2002
46	Ribavirin (Virazole)FDA LinkGeneric 02/2018 - 01/2002
42	Lamivudine (Epivir)FDA Link 05/2017 - 01/2002
31	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
30	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 02/2002
29	Hepatitis B e AntigensIBA 01/2022 - 01/2002
29	Antiviral Agents (Antivirals)IBA 04/2020 - 01/2004
20	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 01/2002
17	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2003
16	entecavir FDA Link 01/2022 - 06/2007
16	AntigensIBA 01/2022 - 01/2002
11	daclatasvirIBA 05/2018 - 04/2013
11	telaprevirIBA 02/2018 - 01/2010
11	Amino Acids FDA Link 09/2015 - 08/2008
10	Pharmaceutical PreparationsIBA 12/2018 - 11/2006
10	asunaprevirIBA 05/2018 - 04/2013
9	Transaminases (Aminotransferases)IBA 02/2015 - 08/2004
8	Proteins (Proteins, Gene)FDA Link 10/2022 - 03/2006
8	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2020 - 01/2003
8	BilirubinIBA 10/2017 - 01/2003
8	adefovir dipivoxil (Hepsera)FDA Link 06/2014 - 01/2004
7	lenvatinibIBA 04/2022 - 01/2020
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 08/2008
7	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 01/2010
7	miriplatinIBA 06/2017 - 01/2011
6	Serum AlbuminIBA 10/2017 - 10/2007
6	lipoarabinomannan (LAM)IBA 05/2017 - 12/2007
6	adefovirIBA 06/2014 - 01/2004
6	Interferon-betaIBA 01/2011 - 01/2008
6	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2011 - 01/2006
5	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2017
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2012
5	Fetal Proteins (Fetoprotein)IBA 04/2021 - 09/2013
5	glecaprevir and pibrentasvirIBA 10/2019 - 01/2018
5	AlbuminsIBA 07/2013 - 01/2009
5	Interferon-alpha (Interferon Alfa)IBA 12/2010 - 02/2002
4	SofosbuvirIBA 10/2022 - 01/2017
4	NucleotidesIBA 02/2022 - 09/2004
4	Tenofovir (Viread)FDA Link 12/2021 - 01/2014
4	Ritonavir (Norvir)FDA Link 04/2018 - 10/2015
4	Hemoglobins (Hemoglobin)IBA 10/2016 - 11/2004
4	Aspartic Acid (Aspartate)FDA Link 04/2010 - 05/2004
3	Cell-Free Nucleic AcidsIBA 04/2022 - 02/2020
3	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2017
3	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2002
3	Circular DNAIBA 01/2022 - 01/2009
3	CanagliflozinIBA 01/2022 - 05/2019
3	TransferasesIBA 04/2021 - 08/2004
3	ombitasvirIBA 04/2018 - 10/2015
3	paritaprevirIBA 04/2018 - 10/2015
3	P-300IBA 04/2018 - 01/2018
3	NucleosidesIBA 05/2017 - 06/2007
3	CreatinineIBA 03/2014 - 03/2013
3	Dihydrotachysterol (AT 10)IBA 01/2014 - 03/2009
3	PlatinumIBA 03/2013 - 04/2009
3	Tyrosine (L-Tyrosine)FDA Link 04/2010 - 05/2004
3	Methionine (L-Methionine)FDA Link 04/2010 - 05/2004
3	Alanine (L-Alanine)FDA Link 01/2010 - 08/2004
2	Peptide Hydrolases (Proteases)FDA Link 10/2022 - 04/2013

Therapy/Procedure

145	Therapeutics 10/2022 - 01/2002
15	Radiofrequency Ablation 02/2019 - 01/2002
6	Retreatment 03/2019 - 04/2003
6	Drug Tapering 10/2013 - 07/2004
4	Aftercare (After-Treatment) 02/2021 - 12/2006
4	Hepatectomy 10/2020 - 07/2005
4	Drug Therapy (Chemotherapy) 09/2013 - 11/2011